Trial Profile
Randomised, Open-label, Active-controlled, Multicentre, Comparative Study to Evaluate the Safety and Efficacy of Ferric Maltol (Iron (III)-Maltol Complex) (ST10) Oral Suspension Compared to Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, Incorporating a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Ferric maltol (Primary) ; Ferrous sulfate
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms FORTIS
- 18 Dec 2023 Planned End Date changed from 1 Sep 2023 to 1 Jul 2024.
- 18 Dec 2023 Planned primary completion date changed from 1 May 2023 to 1 Apr 2024.
- 08 Nov 2021 Status changed from planning to recruiting.